These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 27234989)

  • 1. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
    Gordon EM; Sankhala KK; Chawla N; Chawla SP
    Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin in soft tissue sarcomas.
    Petek BJ; Loggers ET; Pollack SM; Jones RL
    Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
    Barone A; Chi DC; Theoret MR; Chen H; He K; Kufrin D; Helms WS; Subramaniam S; Zhao H; Patel A; Goldberg KB; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Dec; 23(24):7448-7453. PubMed ID: 28774898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
    Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G
    Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin in soft tissue sarcomas.
    Brodowicz T
    Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
    Le Cesne A; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of trabectedin for the treatment of liposarcoma.
    Zijoo R; von Mehren M
    Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Le Cesne A
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
    Schöffski P; Dumez H; Wolter P; Stefan C; Wozniak A; Jimeno J; Van Oosterom AT
    Expert Opin Pharmacother; 2008 Jun; 9(9):1609-18. PubMed ID: 18518789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
    Simpson EL; Rafia R; Stevenson MD; Papaioannou D
    Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
    Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
    Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
    Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
    Vincenzi B; Badalamenti G; Armento G; Silletta M; Spalato Ceruso M; Catania G; Napolitano A; Maltese G; Valeri S; Incorvaia L; Santini D; Tonini G
    Oncology; 2018; 95(1):1-7. PubMed ID: 29510410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
    Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
    Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.